Current and future standards in treatment of myasthenia gravis
about
Pulmonary edema in myasthenic crisisA case for immunosuppression for myoblast transplantation in duchenne muscular dystrophy.Extracorporeal immunoglobulin elimination for the treatment of severe myasthenia gravis.Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine.Quality of life and life circumstances in German myasthenia gravis patients.Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997-2011: a Danish nationwide cohort studyMyasthenia gravis: a review.Plasmapheresis for neurological disorders.Immunosuppressive therapies in myasthenia gravis.Myasthenia gravis in dogs with an emphasis on treatment and critical care management.Current and emerging treatments for the management of myasthenia gravis.Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China.Response of patients with refractory myasthenia gravis to rituximab: a retrospective study.Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis.Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy.Tacrolimus (FK506): Safety and Applications in Reconstructive Surgery.Syndrome of inappropriate secretion of antidiuretic hormone induced by tacrolimus in a patient with systemic lupus erythematosus.Cerebral folate deficiency presenting as adolescent catatonic schizophrenia: a case report.Antigen-specific immunoadsorption of anti-acetylcholine receptor antibodies from sera of patients with myastenia gravis.A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.Tacrolimus monotherapy: a promising option for ocular myasthenia gravis.Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis.Management challenges in muscle-specific tyrosine kinase myasthenia gravis.
P2860
Q33566000-33CC55A2-E3D7-4E3F-83FC-3241F2FAA39BQ33713776-F5259EC7-A76A-48B6-A2FC-1CB1A3239750Q33734287-E99192A5-34C8-4C84-90A1-909160262CC9Q34338594-155C4B58-8CDF-4ECD-8065-0C1A7D863A77Q34366471-19402510-00A7-40AB-903D-9DB764727526Q36195417-88018C60-8DE7-40C4-9F14-89DECF99316AQ36410472-F00FFA22-47F4-4EB8-8205-10577BFB174AQ37600865-A60939B1-5185-456A-982C-7DE8F8D00E95Q37694576-60C3DCCC-EA9A-4534-87F7-4C904E7D32C4Q37883497-40359AB9-6F3B-4112-B94F-69AA3A759B72Q37918361-9DCBE5C4-696B-4B31-8872-93DC8B28D1FDQ38371312-683D7946-1795-46F9-A8C7-AAA3307C819DQ38633453-0579D6C4-EC58-4354-BB03-509772D4B44EQ40369807-F665E7DC-5009-4E68-8A31-B609BEBCEDF8Q41834761-38598F6B-B9A9-4CC7-92BC-AAD8BEF7BB99Q42056355-3BAD03F4-93B1-4625-BB51-EBAFCAC7A1F9Q42926817-FD5E0EB6-AC59-49BE-BED1-62F85488D75BQ43072947-0E5C1B14-43C4-4B39-8A06-5B2DBCFF567BQ43145001-1D38957B-89CA-454C-8B9C-3C7BECA1895DQ45024832-977F6353-4EBC-4181-8AAB-283FA0FB1BB4Q45747372-4A74EA3D-7F66-4A19-90F6-F3D8F552608DQ47570833-5411CBF6-CD10-40D1-A371-756EA4D4B69DQ54464610-27957A58-1B23-4A49-88F1-88FBE14E3C3E
P2860
Current and future standards in treatment of myasthenia gravis
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Current and future standards in treatment of myasthenia gravis
@ast
Current and future standards in treatment of myasthenia gravis
@en
Current and future standards in treatment of myasthenia gravis
@nl
type
label
Current and future standards in treatment of myasthenia gravis
@ast
Current and future standards in treatment of myasthenia gravis
@en
Current and future standards in treatment of myasthenia gravis
@nl
prefLabel
Current and future standards in treatment of myasthenia gravis
@ast
Current and future standards in treatment of myasthenia gravis
@en
Current and future standards in treatment of myasthenia gravis
@nl
P2860
P1433
P1476
Current and future standards in treatment of myasthenia gravis
@en
P2093
P2860
P2888
P304
P356
10.1016/J.NURT.2008.08.011
P577
2008-10-01T00:00:00Z
P5875
P6179
1045448717